|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neck dissection for recurrent and persistent lymph nodes of nasopharyngeal carcinoma after radiotherapy: effect and choice显示文摘目的将在放射疗法以后与周期性、坚持的淋巴节点为鼻咽的癌的病人调查最好的外科的模式。有在放射疗法以后的周期性、坚持的淋巴节点的鼻咽的癌的 88 个病人的临床的数据回顾地被分析的方法。在层次之中的深奥淋巴节点和关系的层次被分析;幸存率和包括激进的颈解剖(RND ) 的外科的模式的周期性的率,修改的激进的颈解剖(MRND ) ,选择的颈解剖(SND ) ,和淋巴节点切除术(LNR ) 被分析;手术后的放射疗法的角色被评估。周期性、坚持的淋巴节点主要在水平 II 定位了的结果( 1 )(55.6%和58.6%,分别地),下次是水平 III 并且很少在水平 IV , V ,并且我,而是层次 IV 的数字, V ,并且我与忍受癌症的淋巴结是相对多于临床的测量的。(2 ) 通常,有涉及水平 III 和 IV 的淋巴节点的病人把另外的层次同时深奥;百分比分别地是 63.6% 和 88.9% 。然而,在水平 II 和 V 的淋巴节点主要被孤立。(3 )5 年的幸存率和整个组的周期性的率分别地是 42.77% 和 22.7% 。(4 ) RND, MRND, SND,和 LMR 组的 5 年的幸存率分别地是 39.75% , 60.00% , 37.87% ,和 44.10% ;差别是不足道的(木头等级 = 1.0, P = 0.8011 ) ;在广泛、本地的外科组之间的周期性的率是不足道的(X 2= 0.470, P = 0.493 ) 。(5 ) 有或没有手术后的放射疗法的病人的 5 年的幸存率分别地是 39.06% 和 45.26% ;差别是不足道的(木头等级 = 0.06, P = 0.8138 ) 。当周期性、坚持的淋巴结是超过一水平时,广泛的外科被推荐的结论包含了或很大或不可移动不那样, SND 应该被执行,手术后的放射疗法如果必要是重要赔偿。 | Liangping Xia Zongyuan Zeng Zhuming Guo Guifang Guo Bei Zhang Huijuan Qiu Feifei Zhou | 2009 | The Chinese-German Journal of Clinical Oncology2009，8，2： | 3 |
| 2 | Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer显示文摘 | Wenzhuo He Chenxi Yin Guifang Guo Chang Jiang Fang Wang Huijuan Qiu Xuxian Chen Ruming Rong Bei Zhang Liangping Xia | 2013 | Medical Oncology2013，，1： | 2 |
| 3 | Surface enhanced Raman scattering substrate with metallic nanogap array fabricated by etching the assembled polystyrene spheres array 显示文摘 | XIA Liangping YANG Zheng YIN Shaoyun | 2013 | Optics Express(S1094-4087)2013，21，11： | 1 |
| 4 | 病例对照Meta分析显示男性乳腺癌与女性乳腺癌预后相同(英文)显示文摘Objective: Male breast cancer (MBC) is a rare disease, and studies to compare the prognosis between the MBC and female breast cancer (FBC) available now were case-control studies and population-based studies, however, with controversial outcomes. To further investigate whether sex affects the prognosis of breast cancer, we performed a meta-analysis based on all the peered papers. Methods: The PubMed database was screened. Subsequently, the hazard ratios (HRs) for overall survival (OS) and disease special survival (DSS), were pooled using the Review Manager 5.0 package. Results: This study comprised of 254 MBC and 733 FBC patients enrolled in six case-control studies. There was no statistically significant heterogeneity among the trials for either outcome variable. The pooled HR showed that there was no significant difference in 5-year or 10-year DSS (HR: 1.25, 95% CI: 0.76-2.08; HR: 1.04, 95% CI: 0.68-1.59) and 5-year or 10-year OS (HR: 0.76, 95% CI: 0.51-1.14; HR: 0.74, 95% CI: 0.54-1.02) between MBCs and FBCs. Conclusion: MBC and FBC with similar prognosis are found in this meta-analysis based on only case-control studies which matched main potential prognostic factors such as age, clinical stage, and time at diagnosis. | Feifei Zhou Rong Huang Jun Jiang Fang Wang Wenzhuo He Guifang Guo Liangping Xia | 2011 | The Chinese-German Journal of Clinical Oncology2011，10，6： | 1 |
| 5 | 中国男性乳腺癌患者临床特征:公开发表文章的总结(英文)显示文摘Objective:The extremely low incidence of male breast cancer (MBC) leads to lack of prospective randomized phase III studies worldwide. Especially in China,all studies on Chinese patients with MBC were based on small sample size and single institute experience. The aim of this study was to provide overall view of characteristics of Chinese patients with MBC by means of summarizing all related papers published in Chinese journals. Methods: An online search was made in CBM,VIP,CNKI,and CBA databases to find all published articles of interest on Chinese patients with MBC. And eight subjects including the proportion of MBC in all breast cancer,age,tumor location,clinical stages,pathological subtypes,treatment modalities,ER/PR expression,and 5-year survival rate were selected to calculate the proportion and their 95% interval confidence. Results: There were 122 papers with 2584 patients enrolled. The basic features of Chinese patients with MBC included:(1) MBC only with a proportion of 1.06% of all the breast cancer; (2) The mean age at diagnosis was 57.6 years old; (3) Tumor mainly located in the areolar region (74.83%) with obvious nipple and/or skin involvement; (4) Nearly 62.62% patients were in early stage before accepting treatment; (5) Infiltrating ductal carcinoma accounted for 79.05% of all pathological subtypes; (6) ER/PR expression rate was 65.86%; (7) Radical resection was up to 86.06% in all surgical modalities; (8) The 5-year survival rate was 57.33%. Conclusion: The results showed in this study were an overall view of Chinese patients with MBC whose characteristics were similar to that reported in the West. Though this study provided a little bit stronger confidence than a single study collected in this paper,studies with more powerful evidence are urgently demanding in China. | Liangping Xia Zhongyu Yuan Xi Wang Jiehua He Bei Zhang Guifang Guo Feifei Zhou Fang Wang | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，6： | 1 |
| 6 | 单药健择治疗老年非小细胞肺癌荟萃分析(英文)显示文摘Objective:Gemcitabine,used as single agent for elderly patients with non-small cell lung cancer (NSCLC),was demonstrated effective in this population based on phase II studies.The aim of this study was to summarize all those phase II studies with the hope to get a comprehensive understanding of gemcitabine efficacy.Methods:The PubMed database was used to search all the papers on NSCLC associated with gemcitabine used as single agent in the first line setting till to March 31st,2010.And the medians and their 95% CI of overall response rate (ORR),disease control rate (DCR),progression free survival (PFS),and overall survival (OS) were calculated.Results:1.There were 7 papers including 410 patients with performance status (PS) ≤ 2 and advanced stage collected.2.The dose-intensities of gemcitabine were 843.75 mg/m 2 /week-1125 mg/m 2 /week in the 4-week schedule,and 666.7 mg/m 2 /week in the 3-week schedule.3.The median age was 73.8 (95% CI was 72.44,75.16) years old;36.1% (95% CI:31.4%,40.7%) of patients with stage IIIB and 60.5% (95% CI:55.8%,65.2%) of patients with stage IV;35.9% (95% CI:31.2%,40.5%) patients were adenocarcinomas and 43.7% (95% CI:38.9%,48.5%) patients were squamous cell carcinomas (SCCs).4.The ORR,DCR,PFS/TTP,and OS were 22.3% (95% CI:18.2%,26.5%),58.4% (95% CI:53.5%,63.4%),3.6 (95% CI:2.9,5.15) months and 6.68 (95% CI:5.4,8.11) months,respectively.Conclusion:Gemcitabine as single agent applied in this special population was effective and can be well tolerated under different doses and usage. | Fang Wang Liangping Xia Guifang Guo Huijuan Qiu Feifei Zhou Wenzhuo He | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，12： | 1 |
| 7 | Sensitivity Enhancement for Surface Plasmon Resonance Imaging Biosensor by Utilizing Gold-Silver Bimetallic Film Configuration 显示文摘 | XIA Liangping YIN Shaoyun GAO Hongtao | 2011 | Plasmouics(S1557-1955)2011，6，2： | 1 |
| 8 | A Flexible Pressure Sensor Based on Poly(dimethylsiloxane) Nanostructures Film显示文摘This paper proposed a flexible pressure sensor based on poly(dimethylsiloxane) nanostructures film and report an efficient,simple,and low-cost fabrication strategy via soft nanoimprint lithography.The pressure sensor can convert external pressure or mechanical deformation into electrical signal to detect pressure and strain changes based on the coupling of triboelectrification and electrostatic induction.To enhance the performance of the pressure sensor,it consists of sub-500 nm resolution on the surface of elastic poly(dimethylsiloxane) sensitive layer and an indium tin oxide electrode thin film.When the pressure applied on the nanostructures layer,triboelectrostatic charges are induced.In the experiment,it measures up to sensitivity of 0.8 V/kPa at frequency of 5 Hz.This study results in potential applications such as wearable smart devices and skin-attachable diagnostics sensing systems. | Man Zhang Liangping Xia Suihu Dang Lifang Shi Axiu Cao Chunlei Du | 2019 | Journal of Microelectronic Manufacturing2019，2，3： | 0 |
| 9 | Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis显示文摘学习的目的是在以前未经治疗的先进非小的房间肺癌症(NSCLC ) 把非铂马甲(马甲组) 的功效和毒性与一个非铂单身者代理人(单个代理人的组) 作比较的目的有老年龄或差的表演地位(PS ) 的病人。PubMed 数据库被屏蔽的方法。随后,为全面幸存( OS )的危险比率( HR )和没有前进的幸存( PFS ),为全面反应的相对风险( RR )评价( ORR )并且一个年幸存,并且为毒性的不同类型的机会比率( ORs )用评论经理 5.0 包裹被分享。这研究 1427 个病人包括了的结果在四注册了使随机化的控制试用。分享的 HR 证明马甲组能增加 ORR (P = 0.002 ) 没有异质(P = 0.64 ) ,并且可能改进 OS (P = 0.01 / P = 0.06 ) 与异质(P < 0.001 ) 。在 PFS 没有重要差别(P = 0.16 ) 并且一个年幸存(P = 0.25 ) 在二个治疗组之间。马甲组比单个代理人的组导致了更多的等级 3/4 嗜中性白血球减少症和 thrombocytopenia (P = 0.02 并且 P = 0.000,分别地) 。等级 3/4 贫血症的发生,呕吐,在二个治疗组之间的 mucositis,便秘,腹泻, neurotoxicity,过敏症,和疲劳是不足道的。结论除了嗜中性白血球减少症和 thrombocytopenia,非铂马甲能增加 ORR,和力量没有更多的副作用的增加,与老年龄或差的 PS 为 NSCLC 病人改进 OS;然而,马甲显示出嗜中性白血球减少症和 thrombocytopenia 的增加的率。马甲的增加不能改进 PFS 和一个年幸存。 | Huijuan Qju Fang Wang Guifang Guo Feifei Zhou Wenzhuo He Liangping Xia | 2011 | The Chinese-German Journal of Clinical Oncology2011，10，3： | 0 |
| 10 | Cetuximab联合化疗二线治疗6例非小细胞肺癌的近期疗效分析(英文)显示文摘Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting.This study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line setting.Methods:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, China.The short-term efficacies and safeties were analyzed.Results:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole group.2.There were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) months.3.There were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).4.There was no treatment-associated death and no cetuximab-associated discontinuation.The incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with chemotherapy.Conclusion:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe. | Fang Wang Liangping Xia Guifang Guo Huijuan Qiu Feifei Zhou Bei Zhang Li Zhang | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，9： | 0 |
| 11 | 爱必妥治疗中国结直肠癌患者的疗效和安全性分析(英文)显示文摘Objective: The aim of this study was to investigate the efficacy and safety profiles of cetuximab, the commonly used monoclonal antibody of epidermal growth factor receptor, based on Chinese patients with colorectal cancer. Methods: All the papers studied on Chinese patients with gastrointestinal cancer treated by cetuximab and found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the cetuximab related side effects such acne-like rash and nail change and hypersensitivity were analyzed too. Results: (1) There were 10 original papers contained total 152 patients with gastrointestinal cancer who were the candidates to analyze the safety profiles, and contained 130 patients with colorectal cancer who were candidates to analyze the efficacy. (2) The disease control rate and response rate in the whole group was 73.5% (95% CI: 65.5%-81.5%) and 29.1% (95% CI: 20.9%-37.3%), respectively; In first-line setting group they were 70.0% (95% CI: 55%-85%) and 41.7% (95% CI: 25.6%-57.8%), respectively; In non-first line setting group they were 71.6% (95% CI: 61.8%-81.4%) and 23.5% (95% CI: 14.3%-32.7%), respectively. The disease control rate between the two line-setting groups was insignificant, but the response rate between the two line-setting groups was significant (P = 0.045). (3) The incidence of acne-like rash was 72.0% (95% CI: 64.8%-79.2%), the degree I-II and degree III-IV account for 56.0% (95% CI: 48.1%-63.9%) and 16.0% (95% CI: 10.1%-21.9%), respectively. No treatment related death, and the hypersensitivity was under control. Conclusion: This study is the first study to summarize the data of Chinese patients with colorectal cancer treated by cetuximab-contained regimen, it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients with colorectal cancer. | Liangping Xia Guifang Guo Huijuan Oiu Bei Zhang Feifei Zhou | 2009 | The Chinese-German Journal of Clinical Oncology2009，8，9： | 0 |
| 12 | 贝伐珠单抗珠联合紫杉类方案治疗中国转移性乳腺癌患者疗效及其相关问题(英文)显示文摘Objective: Bevacizumab has been challenging in the treatment of metastatic breast cancer. To investigate its efficacy, optimal partner to combine with and maintenance therapy, we performed a retrospective study based on Chinese patients with metastatic breast cancer (MBC). Methods: Patients with MBC treated with bevacizumab-contained regimens at the Sun Yat-sen University Cancer Center from 2006 to 2010 were recruited to the study. The primary endpoints were overall survival (OS), time to progression (TTP), objective response rate (ORR), and disease control rate (DCR). These endpoints were analyzed using the Kaplan-Meier and Chi-squared tests, respectively. Results: (1) A total of 229 cycles of bevacizumab with a median cycle of 7 (1-34) were administered among 25 patients. (2) In the whole group, ORR and DCR were 60% (15/25) and 76% (19/25), respectively. The mTTP was 5 months (1-21), mOS from diagnosis was 48 months (13-172), mOS from bevacizumab administration was 24 months (1-45). (3) Both ORR (73.7% vs. 16.7%, P = 0.023) and DCR (94.7% vs. 33.3%, P = 0.005) were significant higher once patients treated with the combination of taxanes-based regimen and bevacizamab when compared with the combination with non-taxanes-based regimens. (4) In the taxanes-based group, no matter bevacizumab used in first line or non-first line, the differences of ORR (P = 0.637) and DCR (P = 0.316) were insignificant. However, the maintenance therapy with bevacizumab will bring more longer TTP (P < 0.001) than those without maintenance therapy. Conclusion: Taxanes-based regimens were the optimal candidate to combine with bevacizumab regardless the timing in palliative setting, however, the maintenance therapy with bevacizumab should be considered once indicated. | Huijuan Qju Wenzhuo He Chenxi Yin Guifang Guo Fang Wang Feifei Zhou Chang Jiang Liangping Xia | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，10： | 0 |
| 13 | 含Cetuximab方案治疗非肠癌消化道肿瘤近期疗效——单中心16例经验总结(英文)显示文摘Objective: Cetuximab is an effective medicine for colorectal cancer bearing wild type Kras. However, few studies of cetuximab on patients with noncolorectal gastrointestinal cancer were available now. The aim of this study was to summarize the efficacy and safety profiles base-on the experiences of 16 patients with noncolorectal gastrointestinal cancer accepted cetuximab-contained regimens treatment. Methods: The clinical data of all patients with noncolorectal gastrointestinal cancer treated by cetuximab combined with chemotherapy and/or radiotherapy from October 1st 2006 to Jun 30th 2009 in Sun Yat-sen University Cancer Center were collected. Results: (1) A total of 16 patients enrolled, including gastric cancer, esophageal carcinoma, pancreatic cancer and cholangiocarcinoma (8, 6, 1 and 1, respectively). The cetuximab was adminis- tered 92 cycles totally with median cycle of 4. (2) PR, SD and PD obtained in 4, 3 and 2 patients respectively in cetuximab + chemotherapy group. The disease control rate, median TTP and median OS were 77.8% (7/9), 3.5 months and 3.5 months, respectively. (3) Both of patients in cetuximab + radiotherapy group achieved PR with median TTP of 4 months and 7 months, with median OS of 14 and 28 months, respectively. (4) In evaluable patients, 3 PR obtained in first-line setting, 1 PD and 1 SD achieved in second-line setting, 2 SD and 1 PD appeared in third-line and more than third-line setting. (5) The commonly side effect was neutropenia, however, rash and hypomagnesemia were the common side effects related to cetuximab. Conclusion: Cetuximab-contained regimens show a promising disease control rate, especially in first-line setting, in patients with noncolorectal gastrointestinal cancer, and the side effects both related to cytotoxic agents and related to cetuximab itself is tolerable and manageable. Of course, more phase Ⅲ clinical trails are needed urgently. | Liangping Xia Guifang Guo Bei Zhang Ruihua Xu Huijuan Qiu Yuming Rong Feifei Zhou Fang Wang | 2009 | The Chinese-German Journal of Clinical Oncology2009，8，11： | 0 |
| 14 | 含白蛋白结合型紫杉醇的化疗方案治疗14例晚期胃癌的近期结果分析(英文)显示文摘Objective: Albumin-bound paclitaxel (abraxane, ABX) has more favorable efficacy and less toxicity than conventional taxanes. However, the data of ABX in advanced gastric cancer (AGC) treatment is unavailable. The current study was designed to summarize our experience in treating AGC patients with ABX. Methods: The clinical data of patients with AGC who had received at least one cycle of ABX-based chemotherapy in Sun Yat-sen University Cancer Center from January 10th 2010 to May 14th 2012 was retrospectively analyzed. Results: A total of 47 cycles of ABX-containing regimens, with a median of 3 cycles (range:1-8 cycles), were administered to 14 patients. Five(35.7%) partial responses and 6 (42.9%) stable diseases were obtained, with a disease control rate (DCR) of 78.6%. The median progression free survival (PFS) and overall survival (OS) were 3.3 and 10.8 months, respectively. Interestingly,patients in the first-line setting achieved a DCR of 100% (8/8). Neutropenia and thrombocytopenia were the main grade 3/4 adverse events with an incidence of 50% in the whole group. However, only 25% patients (2/8) experienced grade 3 neutropenia when ABX in combination with fluoropyrimidines. Conclusion: The activity of ABX-based regimens as first-line therapy for patients with AGC is remarkable, and the toxicity is mild when ABX combined with fluoropyrimidines. Further prospective clinical trials of ABX-based chemotherapy as first-line treatment for AGC are strongly anticipated. | Zheng Yan Liangping Xia Huijuan Qiu Ping Chen Bei Zhang | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，1： | 0 |
| 15 | 西妥昔单抗联合化疗一线治疗非小细胞肺癌疗效:基于公开发表文章的总结(英文)显示文摘Objective:The combination of cetuximab with standard chemotherapy was not widely studied though it was recommended by NCCN 2009 to apply in non-small cell lung cancer(NSCLC) first-line setting.The aim of this study was to summary the efficacy and safety profiles of all the NSCLC patients available in openly published papers treated with above mentioned regimens.Methods:The PubMed database was used to search all the papers on NSCLC associated with cetuximab treatment, and only the clinical trails applied cetuximab combined with doublets cytotoxic chemotherapy in first-line setting till to 30 November 2009 were collected.And the medians and their 95% CI of objective response rate(ORR), progression free survival(PFS), overall survival(OS), and the common adverse events were calculated.Results:(1) Eight papers including 1032 patients were collected, and all cases were at advanced stage.(2) The ratio of male and female patients was 1.6, 50.1% patients were adenocarcinoma and 28.2% patients were squamous cell carcinoma(SCC), 90.0% patients were PS = 0-1, and 78.2% patients were white ethnic.(3) The disease control rate(DCR), ORR, PFS, and OS were 65.2%(95% CI:60.7%-69.7%), 33.2%(95% CI:30.3%-36.1%), 5.0 months(95% CI:4.7-5.3) and 10.9 months(95% CI:9.6-12.2), respectively.Conclusion:This is the first study to summarize the efficacy and safety profiles of cetuximab combined with chemotherapy in NSCLC first-line setting based on all available patients.The addition of cetuximab caused promising prognosis and acceptable side effects excepting higher incidence of neutropenia, and febrile neutropenia. | Liangping Xia Yuming Rong Guifang Guo Huijuan Qiu Feifei Zhou Fang Wang | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，3： | 0 |
| 16 | 肝动脉灌注化疗联合全身化疗作为一线和非一线治疗不可切除肝转移患者的疗效对比(英文)显示文摘Objective: The combination of hepatic arterial chemotherapy(HAIC) and systemic chemotherapy(SYC) has potential effect on colorectal cancer(CRC) patients with unresectable hepatic metastasis. The aim of this retrospective study was to investigate the efficacy and safety of this combined therapeutic regimen on Chinese patients based on single institute experiences. Methods: All 54 patients of this retrospective analysis were diagnosed with CRC with unresectable liver metastasis and received combined HAIC and SYC. Among the patients, 23 of them received HAIC plus SYC when they developed liver metastases as first-line treatment(Group 1), and 31 patients received HAIC plus SYC as non-first-line treatment(Group 2). The different efficacy in two groups was analyzed by SPSS 19.0. Results: The overall response rate(ORR) were 52.2% and 25.8% respectively in Groups 1 and 2(P = 0.047), and the disease control rate(DCR) were 65.2% and 35.5% respectively in Groups 1 and 2(P = 0.031). The median progression-free survival(PFS) were 6.8 and 3.3 months(P = 0.002), the median hepatic progression-free survival(H-PFS) were 8.8 and 3.7 months(P = 0.001), and the median overall survival(OS) were 18.8 and 13.7 months(P = 0.121) in Groups 1 and 2, respectively. No fatal reaction was observed and no significant difference of adverse reaction was found in two groups. Grade 3/4 toxic effects included neutropenia(9.7% in Group 2 only), gastrointestinal reaction(8.7% in Group 1 and 6.5% in Group 2), stomatitis(6.5% in Group 2 only) and hyperbilirubinemia(4.3% in Group 1 only). Conclusion: HAIC combined with SYC showed promising efficacy and safe profiles on CRC patients with unresectable liver metastases. | Ping Chen Bei Zhang Guifang Guo Liangping Xia Huijuan Qiu | 2014 | The Chinese-German Journal of Clinical Oncology2014，13，5： | 0 |
| 17 | 贝伐单抗在中国转移性结直肠癌患者中的疗效及不同治疗线数疗效作用分析(英文)显示文摘Objective: We aimed to evaluate the effect of bevacizumab in the palliative treatment of Chinese metastatic colorectal cancer(mCRC) and its efficacy in different lines. Methods: Patients of mCRC treated with bevacizumab or not at Sun Yat-sen University Cancer Center from 2005 to 2013 were recruited as the study group and control group. The endpoints were objective response rate(ORR), disease control rate(DCR), overall survival(OS) and progression free survival(PFS). The OS and PFS of first-, second- and third-line treatment groups were compared between study group and control group. Results: The median PFS of the study and the control group were 8.2 months(7.0–9.4 months), 5.7 months(4.7–6.6 months), P = 0.001; OS were 26 months(5.4–130.5 months), 18 months(16.6–19.4 months), P < 0.001, respectively. The ORR and DCR of first-, second- and third-line were 30.3%(20/66), 20%(6/30), 17.6%(3/17) and 97%(64/66), 86.7%(26/30), 100%(17/17). In the first-line chemotherapy group, the OS of the study group and the control group were 22.9(5.4–96.7) months and 18(16.6–19.4) months(P < 0.001); PFS were 9.4(8.4–10.4) months and 5.7(4.7–6.6) months(P < 0.001), respectively. While in the second- and third-line setting, only OS were statistically different, PFS had no significant difference. Conclusion: The combination of bevacizumab and chemotherapy had a promising short-term and long-term efficacy in Chinese mCRC patients than those without bevacizumab regimens, and the effect could be better reflected in the first-line treatment. | Chenxi Yin Chang Jiang Fangxin Liao Yuming Rong Wenzhuo He Xiuyu Cai Guifang Guo Huijuan Qiu Xuxian Chen Bei Zhang Liangping Xia | 2014 | The Chinese-German Journal of Clinical Oncology2014，13，4： | 0 |
| 18 | Bevacizumab在中国癌症患者中使用的安全性和有效性的荟萃分析(英文)显示文摘Objective: The aim of this study was to investigate the efficacy and safety profiles of bevacizumab, the commonly used monoclonal antibody and its safety profiles were challenging, based on Chinese cancer patients. Methods: All the papers studied on Chinese cancer patients treated by bevacizumab were found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the bevacizumab related side effects were analyzed too. Results: (1) There were ten original papers contained total 199 patients who were the candidates to analyze the safety profiles, and 115 patients with colorectal cancer in five papers who were candidates to analyze the efficacy. (2) Nine in ten papers set the dose of bevacizumab in 2.5 mg/kg/week - 5 mg/kg/week, and the biweekly was the standard chemotherapy interval. (3) The disease control rate and response rate in Chinese colorectal cancer patients were 85% (95% CI: 79%-92%) and 61% (95% CI: 52%-70%), respectively. (4) The side effects related to bevacizumab were rare and most of them were grades 1-2, and only one case with grade 4 bleeding was recorded and only two cases with discontinuation of bevacizumab since hemoplysis. Also, the grades 3-4 side effects related cytotoxic agents were not common. Conclusion: This study summarized the data of Chinese cancer patients treated by bevacizumab-contained regimens, and it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients. | Huijuan Qiu Wenzhuo He Guifang Guo Xuxian Chen Fang Wang Feifei Zhou Chenxi Yin Liangping Xia | 2011 | The Chinese-German Journal of Clinical Oncology2011，10，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员